Evaluation of the Pharmacokinetics of Microdose Midazolam, Dabigatran, Pitavastatin, Atorvastatin and Rosuvastatin in Diabetic Patients - Trial NCT06273215
Access comprehensive clinical trial information for NCT06273215 through Pure Global AI's free database. This Phase 4 trial is sponsored by Peking University Third Hospital and is currently Recruiting. The study focuses on Diabetes. Target enrollment is 48 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
The combinations of 10 µg midazolam, 375 µg dabigatran etexilate, 10 µg pitavastatin, 50 µg rosuvastatin, and 100 µg atorvastatin were administered to diabetic patients on an empty stomach.
Interventional
drug
Sponsor & Location
Peking University Third Hospital
Timeline & Enrollment
Phase 4
Mar 05, 2023
Dec 31, 2025
Primary Outcome
Pharmacokinetics of study drug
Summary
1.To explore the functional changes of P-gp, CYP3A4, OATP1B and BCRP in Diabetic patients
 (including the non-obese T2DM, obese T2DM, elderly T2DM, and T1DM).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06273215
Non-Device Trial